<DOC>
	<DOCNO>NCT00557921</DOCNO>
	<brief_summary>The purpose COGENT-1 clinical trial determine whether CGT-2168 ( clopidogrel omeprazole ) compare clopidogrel safe effective reduce incidence gastrointestinal bleeding symptomatic ulcer disease , set concomitant aspirin therapy . Antiplatelet therapy essential element care patient atherothrombotic disease . Bleeding fundamental adverse effect antiplatelet drug include aspirin , clopidogrel dual antiplatelet regimen . The gastrointestinal tract common site bleeding related antiplatelet therapy , typically connection peptic ulcer disease . Recently publish study suggest use clopidogrel carry gastrointestinal bleeding risk similar aspirin non-aspirin non-steroidal anti-inflammatory drug . Patients take two drug ( clopidogrel , aspirin and/or non-aspirin NSAIDs ) expose even high risk bleed ulcer disease . Cogentus Pharmaceuticals launch phase 3 trial novel combination product , CGT-2168 , potential significantly reduce problem increase patient safety . CGT-2168 combine standard dosage clopidogrel gastroprotectant ( omeprazole ) once-daily pill may reduce likelihood adverse gastrointestinal event .</brief_summary>
	<brief_title>Clopidogrel Optimization Gastrointestinal Events ( COGENT-1 )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Patients requirement clopidogrel therapy concomitant aspirin anticipate least next 12 month . Specific condition may confer need longterm clopidogrel + aspirin therapy may include nonST segment elevation acute coronary syndrome ( unstable angina/nonQwave MI ) , ST segment elevation acute MI ) , new placement coronary artery stent . For woman childbearing potential , negative pregnancy test prior randomization agreement use effective method birth control study . Able provide write informed consent base competent mental status . Patients currently hospitalize discharge anticipate within 48 hour randomization . Requirement current chronic use proton pump inhibitor , H2 receptor blocker , sucralfate misoprostol . Erosive esophagitis , esophageal gastric variceal disease , nonendoscopic gastric surgery . Patients history GERD/erosive esophagitis dyspepsia currently require proton pump blocker eligible . Receipt &gt; 21 day clopidogrel another thienopyridine prior randomization . Oral anticoagulation safely discontinue duration study . Recent fibrinolytic therapy . Scheduled percutaneous coronary intervention ( PCI ) . Patients may enrol upon completion PCI . Recent ( &lt; 30 day prior randomization ) schedule coronary artery bypass graft ( CABG ) surgery . Cardiogenic shock time randomization , refractory ventricular arrhythmia , congestive heart failure ( NY Heart Association class IV ) . Active pathological bleeding history hereditary acquire hemostatic disorder . History hemorrhagic stroke , intracranial neoplasm , arteriovenous malformation aneurysm . Systemic corticosteroid except lowdose oral corticosteroid equivalent prednisone &lt; equal 5 mg/day . Allergy contraindication clopidogrel thienopyridine drug , omeprazole proton pump inhibitor drug , aspirin salicylate derivative , study drug ingredient . Treatment within 30 day prior randomization investigational drug device include investigational coronary artery stent currently enrol another interventional drug device study . Women pregnant breastfeeding . Life expectancy le 12 month . Laboratory abnormality screen clinically significant outside protocolallowed limit , condition precludes participation study opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>ACS</keyword>
	<keyword>CAD</keyword>
	<keyword>MI</keyword>
	<keyword>PCI</keyword>
	<keyword>PTCA</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>STEMI</keyword>
	<keyword>acute coronary syndrome</keyword>
	<keyword>cerebrovascular disorder</keyword>
	<keyword>coronary artery stent placement</keyword>
	<keyword>coronary thrombosis</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>percutaneous coronary intervention</keyword>
	<keyword>percutaneous transluminal coronary angioplasty</keyword>
	<keyword>peripheral vascular disease</keyword>
	<keyword>duodenal obstruction</keyword>
	<keyword>duodenal ulcer</keyword>
	<keyword>dyspepsia</keyword>
	<keyword>esophagitis , peptic</keyword>
	<keyword>gastric outlet obstruction</keyword>
	<keyword>gastroduodenal ulcer</keyword>
	<keyword>gastroesophageal reflux disease</keyword>
	<keyword>gastrointestinal hemorrhage</keyword>
	<keyword>peptic ulcer</keyword>
	<keyword>peptic ulcer perforation</keyword>
</DOC>